Evidence map›Paper›PMID 35903939›Full record

ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Clot Stiffness Measured By Seer Sonorheometry As a Marker Of Poor Prognosis In Hospitalized COVID-19 Patients.

Francisco José López-Jaime, Ihosvany Fernández-Bello, Sandra Martín-Téllez, Alberto Doblas-Márquez, Yohannes Tesfay, Ignacio Márquez-Gómez, José María Reguera-Iglesias, Manuel Isidro Muñoz-Pérez, Adrián Montaño

Open access · goldAbstract read
In one paragraph

Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Francisco José López-JaimeUnidad de Hemostasia y Trombosis, 16330Hospital Universitario Regional de Málaga, IBIMA, Málaga, Spain.
Ihosvany Fernández-BelloUnidad de Hemostasia y Trombosis, 16330Hospital Universitario Regional de Málaga, IBIMA, Málaga, Spain.
Sandra Martín-TéllezUnidad de Hemostasia y Trombosis, 16330Hospital Universitario Regional de Málaga, IBIMA, Málaga, Spain.
Alberto Doblas-MárquezUnidad de Hemostasia y Trombosis, 16330Hospital Universitario Regional de Málaga, IBIMA, Málaga, Spain.
Yohannes Tesfay559742Hemosonics, LLC Company, Durham County, USA.
Ignacio Márquez-GómezServicio de Enfermedades Infecciosas, 16330Hospital Universitario Regional de Málaga, Málaga, Spain.
José María Reguera-IglesiasServicio de Enfermedades Infecciosas, 16330Hospital Universitario Regional de Málaga, Málaga, Spain.
Manuel Isidro Muñoz-PérezUnidad de Hemostasia y Trombosis, 16330Hospital Universitario Regional de Málaga, IBIMA, Málaga, Spain.
Adrián MontañoUnidad de Hemostasia y Trombosis, 16330Hospital Universitario Regional de Málaga, IBIMA, Málaga, Spain.ORCID https://orcid.org/0000-0002-3178-6726
Hospital Regional Universitario de Málaga · ESHemoSonics (United States) · USUniversidad de Salamanca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A high risk of thrombotic complications has been observed among severely ill COVID-19 patients. Viscoelastic tests (VET) have shown a hypercoagulable profile in these patients, although so far there is no clear evidence on the use of these tools as predictors of risk in the clinical course of patients. In this study we aimed to evaluate the association between Quantra® sonorheometry VET parameters, standard coagulation tests and inflammatory markers in 69 patients with COVID-19 on hospital admission with disease severity and outcome. Inflammatory markers were elevated in a high percentage of patients, as were coagulation-related parameters such as fibrinogen and D-dimer levels. Quantra® sonorheometry analysis revealed increased clot stiffness (CS), especially due to increased fibrinogen contribution (FCS) in 63.7%. Analysis of clot stability to lysis (CSL) on the Quantra showed a value of 100%, suggesting hypofibrinolysis, in 32.4%. Age > 65 years, elevated values of fibrinogen, D-dimer, LDH, increased CS and CSL were significantly associated with worsening disease. The combination of elevated FCS and D-dimer values showed a particularly high prognostic value in distinguishing patients with severe symptomatology. In conclusion, FCS measured by Quantra® system and its combination with D-dimer could be established as a powerful tool to identify poor prognosis in COVID-19 patients on hospital admission.

Indexed as

COVID-19ThrombelastographyAgedBiomarkersBlood Coagulation TestsFibrin Fibrinogen Degradation ProductsFibrinogenHumansPrognosisBiomarkersFibrin Fibrinogen Degradation ProductsFibrinogencommunicable diseasesCOVID-19diagnosishematologythrombosis

Identifiers

PMID35903939
PMCPMC9340415
OpenAlexW4288495231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.